HealthRX GLP-1 Review (2026): Pricing, Coverage, and Tradeoffs

Item: HealthRX
Author: RangeYourself

HealthRX review, semaglutide compounded, $99/mo on the 12-month plan; from $133/mo on the 3-month plan, verified 2026-08-21 on healthrx.com (unchanged since 2026-07-18). same price at every dose., tirzepatide compounded, $179/mo on the 12-month plan; from $209/mo on the 3-month plan, verified 2026-08-21 on healthrx.com (unchanged since 2026-07-18). same price at every dose.. A low, transparent flat price on compounded GLP-1 with no insurance and fast shipping. Independent 2026 review from RangeYourself.

By RangeYourselfLast verified 2026-08-21

Quick take

HealthRX is compounded semaglutide and tirzepatide (503a), priced as commitment-tier plans (3/6/12-month), one flat price at every dose. Best for: A low, transparent flat price on compounded GLP-1 with no insurance and fast shipping. Watch out for: The lowest advertised rate requires the 12-month commitment plan; the 3-month plan is the higher entry tier, and any 1-month option is not publicly priced. Confirm your plan term and dose price at checkout.

Pricing summary

Price verified: 2026-08-21 (checked against the provider’s public pricing surface)
All-in monthly cost: $99/month (medication included), 12-month plan rate
Semaglutide: Compounded, $99/mo on the 12-month plan; from $133/mo on the 3-month plan, verified 2026-08-21 on healthrx.com (unchanged since 2026-07-18). Same price at every dose.
Tirzepatide: Compounded, $179/mo on the 12-month plan; from $209/mo on the 3-month plan, verified 2026-08-21 on healthrx.com (unchanged since 2026-07-18). Same price at every dose.
Compounded vs brand-name: Compounded only
Insurance accepted: No insurance-billing path published (cash-pay); confirm at signup
Consult type: Async questionnaire, per the provider’s published flow
Dose-escalation pricing: Flat price per medication regardless of dose ('Same price at every dose'). The per-month rate is set by plan term: semaglutide $99/mo (12-month) or from $133/mo (3-month); tirzepatide $179/mo (12-month) or from $209/mo (3-month), verified 2026-07-18. A 6-month tier is referenced by the affiliate program but is not itemized on the public homepage; confirm at checkout.
Refund policy: 30-day money-back; full refund if a licensed provider does not approve you; cancel anytime in one click.
States served: All 50 US states + Washington, D.C.

See HealthRX pricing →

Choose HealthRX if

You want a low, transparent flat price on compounded semaglutide or tirzepatide with no insurance required
You're comfortable committing to a 3- or 12-month plan to lock the lowest per-month rate
You want the same price at every dose as you escalate
You value fast cold-chain shipping to all 50 states

Skip HealthRX if

You want a true no-commitment month-to-month price, or a named pharmacy/medical group disclosed up front..

Contraindications and clinical notes

Standard GLP-1 contraindications (personal/family history of MTC or MEN 2). Compounded, not FDA-approved, prescription required after a US board-certified physician review.. Talk to a clinician about personal or family history of medullary thyroid carcinoma, MEN 2, pancreatitis, or other conditions before starting any GLP-1 medication.

Verified programs that cost less than HealthRX

HealthRX’s own verified figure is $99/mo (12-month plan rate). Every program below carries a lower all-in monthly price that we verified on the provider’s own pricing page, ranked lowest first as of September 3, 2026.

1.Embody
$69/mo (limited-time promo), verified August 21, 2026
See pricing →

Prices are each provider’s own published all-in monthly figure at the plan term shown, verified on the date listed. RangeYourself may earn a commission from some programs; that can only break an exact tie between verified equals and never changes the price order.

How HealthRX compares

Frequently asked questions

How much does HealthRX cost per month?

HealthRX's lowest verified rate is $99/month with compounded medication included, and that figure is its 12-month plan rate rather than a month-to-month price. Semaglutide: Compounded, $99/mo on the 12-month plan; from $133/mo on the 3-month plan, verified 2026-08-21 on healthrx.com (unchanged since 2026-07-18). Same price at every dose.; tirzepatide: Compounded, $179/mo on the 12-month plan; from $209/mo on the 3-month plan, verified 2026-08-21 on healthrx.com (unchanged since 2026-07-18). Same price at every dose.. Flat price per medication regardless of dose ('Same price at every dose'). The per-month rate is set by plan term: semaglutide $99/mo (12-month) or from $133/mo (3-month); tirzepatide $179/mo (12-month) or from $209/mo (3-month), verified 2026-07-18. A 6-month tier is referenced by the affiliate program but is not itemized on the public homepage; confirm at checkout.

Does HealthRX accept insurance?

HealthRX publishes cash-pay prices and we found no insurance-billing path on its own site. Where a provider's own FAQ leaves the door open, the answer sits inside its intake flow, which we do not enter, so confirm at signup rather than treating this as settled. If you want insurance-billed brand-name GLP-1, see our list of GLP-1 programs that accept insurance.

What states does HealthRX serve?

HealthRX ships medication to all 50 US states plus Washington, D.C.

Is HealthRX compounded or brand-name?

HealthRX prescribes compounded semaglutide and tirzepatide via state-licensed 503A pharmacies or 503B outsourcing facilities. Compounded medication is not individually FDA-approved. The shortage-era compounding pathway ended after the FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so compounding now proceeds under the ordinary rules for individual patients.

What's the catch with HealthRX?

The lowest advertised rate requires the 12-month commitment plan; the 3-month plan is the higher entry tier, and any 1-month option is not publicly priced. Confirm your plan term and dose price at checkout. Avoid if: you want a true no-commitment month-to-month price, or a named pharmacy/medical group disclosed up front..

Related guides

HealthRX availability by state

GLP-1 programs in California , where HealthRX ships and how it stacks up locally.
GLP-1 programs in Texas , where HealthRX ships and how it stacks up locally.
GLP-1 programs in Florida , where HealthRX ships and how it stacks up locally.
GLP-1 programs in New York , where HealthRX ships and how it stacks up locally.
GLP-1 programs in Illinois , where HealthRX ships and how it stacks up locally.

About compounded GLP-1 medicationsCompounded semaglutide and tirzepatide are not FDA-approved finished products. They are prepared by state-licensed 503A pharmacies or 503B outsourcing facilities and are not individually reviewed by the FDA for safety, effectiveness, or quality. Compounders describe these preparations as using the same active ingredient as the approved medicines; the FDA has warned that some compounded products use salt forms, semaglutide sodium or semaglutide acetate, that it considers different active ingredients from the approved drug, and has issued warning letters over marketing that presents a compounded preparation as interchangeable with an approved one. The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so the shortage-era pathway for broad compounding of these drugs has ended. Compounding now proceeds under the ordinary rules: a 503A pharmacy compounding for an individual patient on a prescription, or a 503B outsourcing facility, which compounds in bulk under CGMP and FDA registration rather than per patient. Those rules generally do not cover a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for an individual patient. Talk to a clinician about contraindications including personal or family history of medullary thyroid carcinoma or MEN 2. RangeYourself does not provide medical advice, does not guarantee a prescription, and does not guarantee weight-loss results.

About these products

These are compounded preparations, not FDA-approved for anti-aging or longevity indications, and a prescription from a licensed clinician is required. Compounding pharmacies are not individually reviewed by the FDA for the safety or effectiveness of a specific compounded product. We rank and describe these programs on price and access only, never on efficacy, outcomes, or benefit claims, and we do not repeat a provider’s own marketing claims as independently verified fact.

NAD+: NAD+ is not an FDA-approved drug, and its compounding status is not settled in its favor. In a warning letter to GenoGenix LLC dated January 20, 2026 (WL#718739), the FDA stated that NAD+ is not eligible for compounding by a 503B outsourcing facility. We could not identify a clear 503A pathway for it either: it has no USP monograph and is not a component of an approved drug. A Class I recall of an NAD+ injectable over endotoxin contamination is also on the record. We rank the programs on this page on published price only, and price is not a safety, quality, or eligibility signal here, confirm sourcing, the dispensing pharmacy, and any state restrictions directly with the provider before purchase, and discuss it with a prescribing clinician.

Sermorelin: not currently marketed as an FDA-approved product; it is compounded by licensed pharmacies for individual patients.

PT-141 (bremelanotide): FDA-approved only as Vyleesi, for hypoactive sexual desire disorder in premenopausal women. Any other use, including compounded versions sold for general sexual-health purposes, is off-label.

These peptide and longevity products are not identical to, and are never described here as generic or equivalent to, any FDA-approved drug, and unlike compounded GLP-1 medication most of them have no FDA-approved counterpart at all. State availability varies by provider and by product, several programs listed here disclose per-state restrictions; confirm eligibility in your state before purchase. RangeYourself does not provide medical advice and does not guarantee a prescription.

RangeYourself is reader-supported. We may earn a commission when you click on certain links, at no extra cost to you. Editorial recommendations are made independently. Pricing reflects publicly listed entry tiers verified on 2026-08-21 and may change.